Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): Challenges in developing management strategies

Medical Journal of Australia

Volumn 186, Issue 2, 2007, Pages 55-56

  Asiedu, Kingsley ^a   Wansbrough Jones, Mark ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; DNA; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

AFRICA; ANTIBIOTIC RESISTANCE; AUSTRALIA; BACTERIUM CULTURE; BURULI ULCER; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; DNA FINGERPRINTING; DRUG CHOICE; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; MEDICAL RESEARCH; MICROSCOPY; MONOTHERAPY; MYCOBACTERIUM ULCERANS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAPULAR RASH; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SKIN TRANSPLANTATION; TREATMENT OUTCOME; ULCER HEALING; UNSPECIFIED SIDE EFFECT; WATER CONTAMINATION;

EID: 33846599365     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb00799.x     Document Type: Editorial

References (14)

1. MacCallum F, Tolhurst JC, Buckle G, Sissons HA. A new Mycobacterium in man. I: Clinical aspects. J Pathol Bacteriol 1948; 60: 93-122.
2. Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer - Mycobacterium ulcerans infection. Geneva: World Health Organization, 2000.
3. Mve-Obiang A, Lee RE, Portaels F, Small PL. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 2003; 71: 774-783.
4. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity [review]. Lancet 2006; 367: 1849-1858.
5. Ji B, Lefrancois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chermother 2006; 50: 1921-1926.
6. Marsollier L, Prevot G, Honore N, et al. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin, Int J Antimicrob Agents 2003; 22: 562-566.
7. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampicin-streptomycin in the treatment of early human M. ulcerans disease. Antimicrob Agents Chemother 2005; 49: 3182-3186.
8. Chauty A. Antibiotic treatment at Pobè Centre in Benin - update. In: World Health Organization. Abstracts (draft). Annual meeting of the WHO global Buruli ulcer initiative, 15-17 March 2006. Geneva: WHO, 2006: 54-55. http://www.who.int/buruli/information/Abstracts-Draft.pdf (accessed Nov 2006).
9. Rondini S, Horsfield C, Mensah-Quainoo E, et al. Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 2006, 208: 119-128.
10. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61.
11. Johnson PDR, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68.
12. Lavender CJ, Senanayake SN, Fyfe JAM, et al. First case of Mycobacterium ulcerans disease (Bairnsdale or Buruli ulcer) acquired in New South Wales. Med J Aust 2007; 186: 62-63.
13. Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35: 1696-1700.
14. Phillips R, Horsfield C, Kuijper S, et al. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol 2005; 43: 3650-3656.